title: Omnipaque vs. Hexabrix in intravenous DSA of the carotid arteries: randomized double-blind crossover study.
abstract: A randomized double-blind crossover study using Omnipaque 350 mg l/ml (iohexol) and Hexabrix 320 mg l/ml (ioxaglate) in 53 patients undergoing intravenous digital subtraction angiography of the carotid arteries revealed no significant differences in image quality. Some differences were found in subjective side effects that favored Omnipaque. Nausea was reported in four patients after injection of Hexabrix, and a metallic taste was significantly more frequent (p less than 0.01) with this contrast medium. The patients' preference for Omnipaque was also statistically significant (p less than 0.01). It was concluded that both contrast media are suitable for intravenous digital subtraction angiography.
authors.forename: P H
authors.initials: PH
authors.lastname: Nakstad
authors.forename: S J
authors.initials: SJ
authors.lastname: Bakke
authors.forename: O
authors.initials: O
authors.lastname: Kjartansson
authors.forename: J
authors.initials: J
authors.lastname: von Krogh
mesh_terms: D000328:Adult; D000368:Aged; D000792:Angiography / Q000379:methods*; D002339:Carotid Arteries / Q000000981:diagnostic imaging*; D002986:Clinical Trials as Topic; D003287:Contrast Media; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D007485:Ioxaglic Acid; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013382:Subtraction Technique; D014283:Triiodobenzoic Acids / Q000009:adverse effects
chemical_list: D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D007485:Ioxaglic Acid